Article
Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.
EBioMedicine - 1 Jun 2015
Shen Yang, Fu Ya-Kai, Zhu Yong-Mei, Lou Yin-Jun, Gu Zhao-Hui, Shi Jing-Yi, Chen Bing, Chen Chao, Zhu Hong-Hu, Hu Jiong, Zhao Wei-Li, Mi Jian-Qing, Chen Li, Zhu Hong-Ming, Shen Zhi-Xiang, Jin Jie, Wang Zhen-Yi, Li Jun-Min, Chen Zhu, Chen Sai-Juan
Abstract excerpt
BACKGROUND: Acute promyelocytic leukemia (APL) is a model for synergistic target cancer therapy using all-trans retinoic acid (ATRA) and arsenic trioxide (ATO), which yields a very high 5-year overall survival (OS) rate of 85 to 90%. Nevertheless, about 15% of APL patients still get early death or relapse. We performed this study to address the possible impact of additional gene mutations on the outcome of APL....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.